Human cell transformation systems revealed that RAL-GEF signaling is particularly required for oncogenic RAS function in human cancer. Murine Kras-driven lung cancer models have confirmed the key ...

In non-small cell lung cancer (NSCLC), the leading cause of cancer-related death, KRAS mutations are found in 25-30% of all cases with non-squamous histology. The KRAS-G12C mutation, specifically ...

This suggests a model in which lung damage from smoking or ... There are multiple cancer drugs that specifically target mutated KRAS, but these mostly deliver only limited clinical benefit.

Human cell transformation systems revealed that RAL-GEF signaling is particularly required for oncogenic RAS function in human cancer. Murine Kras-driven lung cancer models have confirmed the key ...

Merck & Co’s Keytruda reigns supreme among immunotherapies for non-small cell lung cancer (NSCLC), and new data looks set to consolidate that position even further with new data in KRAS-positive ...

Next, using two mouse models of KRAS-driven lung cancer, investigators inactivated ... the spatial precision facilitated by ...

KRAS G12C is the most common form of KRAS mutation in lung cancer, while G12D is found more commonly in other diseases like pancreatic and colorectal cancers. Dr Hu Tao, co-founder and chief ...

the team used a model with tobacco carcinogen exposure, which creates lung damage like that incurred by cigarette smoke. They ...

A new collaborative study from Karolinska Institutet published in Science Advances shows that the levels of mitochondrial DNA ...

Current and former smokers are to be invited to the country’s first mobile lung health check, which aims to improve the early detection of lung cancer.

Recent research from the University of Helsinki sheds new light on the behavior of the KRAS gene in two of the deadliest cancers—pancreatic and colorectal cancer. These findings suggest ...

Published in Cancer Research and Nature Communications, the studies demonstrate that the loss of the normal version of the KRAS gene can accelerate the growth of pancreatic and colorectal cancers.